Skip to Content
77 Mass Ave

Anthrax Makeover

Researchers harness deadly bacteria’s delivery mechanism to fight cancer.
December 18, 2014

Bacillus anthracis bacteria have exceptionally efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of MIT researchers has now hijacked that delivery system for a different purpose: administering cancer drugs.

Bacillus anthracis bacteria, magnified more than 12,000 times.

“Anthrax toxin is a professional at delivering large enzymes into cells,” says Bradley Pentelute, an assistant professor of chemistry. “We wondered if we could render anthrax toxin nontoxic and use it as a platform to deliver antibody drugs into cells.”

In a recent paper, Pentelute and colleagues showed that they could use a disarmed version of the anthrax toxin to deliver two proteins known as antibody mimics, which can kill cancer cells by disrupting specific proteins inside the cells.

Antibodies—natural proteins the body produces to bind to foreign invaders—are a rapidly growing area of pharmaceutical development. Inspired by natural protein interactions, scientists have designed new antibodies that can disrupt proteins such as the HER2 receptor, found on the surfaces of some cancer cells. The resulting drug, Herceptin, has successfully been used to treat breast tumors that produce more than the usual amount of HER2 receptor.

Several antibody drugs have been developed to target other receptors found on cancer-cell surfaces. However, the potential usefulness of this approach has been limited by the difficulty of getting proteins inside cells. This means that many potential targets have been “undruggable,” Pentelute says.

For inspiration to solve this problem, Pentelute and his colleagues turned to nature. The anthrax toxin has three major components. One is a protein called protective antigen (PA), which binds to receptors called TEM8 and CMG2 that are found on most mammalian cells. Once PA attaches to the cell, it forms a docking site for two anthrax proteins called lethal factor (LF) and edema factor (EF). These proteins are pumped into the cell through a narrow pore and disrupt cellular processes, often resulting in the cell’s death.

However, this system can be made harmless by removing the toxic sections of the LF and EF proteins, leaving behind the sections that allow the proteins to penetrate cells. The MIT team removed the toxic sections and replaced them with the antibody mimics, allowing these cargo proteins to catch a ride into cells through the PA channel.

After successfully interfering with several cancer proteins in tumor cells grown in the lab, the team is now testing this approach to treat tumors in mice.

Keep Reading

Most Popular

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

Europe's AI Act concept
Europe's AI Act concept

A quick guide to the most important AI law you’ve never heard of

The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.

Uber Autonomous Vehicles parked in a lot
Uber Autonomous Vehicles parked in a lot

It will soon be easy for self-driving cars to hide in plain sight. We shouldn’t let them.

If they ever hit our roads for real, other drivers need to know exactly what they are.

crypto winter concept
crypto winter concept

Crypto is weathering a bitter storm. Some still hold on for dear life.

When a cryptocurrency’s value is theoretical, what happens if people quit believing?

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.